Clinical Trial Goal
To find out:
- The highest dose of DR-01 that’s safe to give
- If DR-01 is safe and works well to treat large granulocytic leukemia or certain T-cell or NK-cell lymphomas that have relapsed or are refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have large granulocytic leukemia or certain T-cell or NK-cell lymphomas that have relapsed or are refractory. Some examples include:
- Aggressive NK cell leukemia
- Cutaneous T-cell lymphoma (CTCL)
- EBV T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Do not have cancer cells in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
DR-01 is monoclonal antibody that targets CD94 in certain cells.
You’ll get treatment in cycles that last about a month. In each cycle, you'll get:
You’ll get treatment in cycles that last about a month. In each cycle, you'll get:
- DR-01 – The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 2 years. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved has not yet approved DR-01.
Locations
Sponsors
lead: Dren Bio
